Dr. ElMaraachli is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 W Arbor Dr
San Diego, CA 92103Phone+1 858-657-7125Fax+1 619-543-3032
Summary
- Dr. Wael ElMaraachli, MD, is a pulmonologist based in San Diego, CA, who specializes in Pulmonary and Critical Care Medicine. He is an Associate Clinical Professor at the University of California San Diego School of Medicine. He completed his medical education at the American University of Beirut before pursuing a residency at the University of Iowa and a fellowship at the University of California San Diego Medical Center. His expertise lies in general pulmonary medicine, critical care medicine, and more specifically in Bronchiectasis and mycobacterial lung infections. He has several significant publications to his name, notably in the International Journal of Tuberculosis and Lung Disease, Frontiers in Microbiology, and Clinics in Chest Medicine. He is also involved in various clinical trials focused on evaluating treatments for pulmonary Bronchiectasis and Mycobacterium Avium Complex Disease.
Education & Training
- University of California (San Diego) Medical CenterFellowship, Pulmonary Disease and Critical Care Medicine, 2009 - 2012
- University of Iowa Hospitals and ClinicsResidency, Internal Medicine, 2003 - 2007
- American University of Beirut Faculty of MedicineClass of 2002
Certifications & Licensure
- CA State Medical License 2008 - 2026
- FL State Medical License 2019 - 2023
- IA State Medical License 2003 - 2009
- American Board of Internal Medicine Critical Care Medicine
- American Board of Internal Medicine Pulmonary Disease
Clinical Trials
- Study to Evaluate Efficacy of LAI When Added to Multi-drug Regimen Compared to Multi-drug Regimen Alone Start of enrollment: 2015 May 27
- Open-label Safety Extension Study Assessing Safety and Tolerability of LAI in Patients Who Participated in Study INS-212 Start of enrollment: 2016 Feb 05
- Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease Start of enrollment: 2019 Feb 22
Publications & Presentations
PubMed
- 3 citationsNovel and reported compensatory mutations ingenes found in drug resistant tuberculosis outbreaks.Derek Conkle-Gutierrez, Sarah M Ramirez-Busby, Bria M Gorman, Afif Elghraoui, Sven Hoffner
Frontiers in Microbiology. 2023-01-01 - 50 citationsRifabutin and rifampin resistance levels and associated rpoB mutations in clinical isolates of Mycobacterium tuberculosis complexZenda L. Berrada, Shou-Yean Grace Lin, Timothy C. Rodwell, Duylinh Nguyen, Gisela F. Schecter
Diagnostic Microbiology and Infectious Disease. 2016-06-01 - 11 citationsUsing Cystic Fibrosis Therapies for Non–Cystic Fibrosis BronchiectasisWael ElMaraachli, Douglas Conrad, Angela C.C. Wang
Clinics in Chest Medicine. 2016-03-01
Press Mentions
- Clinical Year in Review 3: Panelists Review Papers in Critical Care, Cystic Fibrosis, Sepsis, and BronchiectasisMay 18th, 2022
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: